● 3月のコラム
●● メディカル情報生命専攻
●●● 山岸誠准教授
私事になるが、2026年1月16日、第8回日本医療研究開発大賞の表彰式に出席した。製薬企業と一緒に進めてきた、難治性血液がんに対する新規治療薬の開発が評価され、内閣総理大臣賞を賜った。
人生で二度とない機会だと思い、首相官邸へ。普段ニュースで目にする官邸の玄関フロアは、想像以上に広く、どこか静謐な雰囲気が漂っていた。当日はイタリア首相の来訪も重なり、館内には季節の花が随所に飾られ、中庭の景観もひときわ印象的だった。2階大ホールで行われた表彰式では、首相から賞状と楯を直接受け取り、研究開発への積極的な投資の重要性などのお話を伺うことができた。
振り返ると、創薬のきっかけになった研究成果を発見したのは2011年頃だ。新領域で学位を取得し、ポスドクとして研究を本格的に始めた時期でもある。東日本大震災の計画停電や余震の合間を縫って、実験していた日々を今でもよく覚えている。そこから研究が進み、薬として販売に至った2022年までには10年以上経過した。今も適応拡大や併用療法などの開発が続いている。「新薬開発で10年は短い」と言われることもあるが、想定と異なる研究データに直面したり、論文投稿で何度もリジェクトを経験したりと、平坦な道のりではなかったように思う。これは生物学や医学に限った話ではなく、おそらくどの分野の研究でも同じなのだろう。
それでも道中楽しみながらもここまで来られたのは、研究室の仲間、共同研究者、産官学連携に関わる皆様、研究を支えてくれた多くの人たちがいたからだと、あらためて思う。研究はまだ道半ばで、多くの課題が残されている。今回の受賞を励みに、生命現象の解明と医療への還元を目指して、これからも研究を進めていきたい。
● March Column
●● Department of Computational Biology and Medical Sciences
●●● Makoto YAMAGISHI, Associate Professor
On a personal note, I attended the award ceremony for the 8th Japan Medical Research and Development Grand Prize on January 16, 2026. Our development of a new therapeutic drug for refractory hematologic malignancies in collaboration with a pharmaceutical company was recognized. And we were deeply honored to receive the Prime Minister’s Award.
Considering it a once-in-a-lifetime opportunity, I visited the Prime Minister’s Office. The entrance hall, which I usually see on the news, was far more spacious than I had imagined, with a serene atmosphere. The Italian Prime Minister was also visiting that day, so seasonal flowers were displayed throughout the residence, with the courtyard view being particularly impressive. At the award ceremony held in the large hall on the second floor, I received the certificate and plaque directly from the Prime Minister and heard remarks on the importance of proactive investment in research and development.
Looking back, I made the research discovery that led to the development of this drug around 2011. That was also the time I obtained my degree from GSFS and really began my research as a postdoctoral fellow. I still remember conducting experiments in between planned power outages and aftershocks following the Great East Japan Earthquake. From that starting point, more than a decade passed before the drug reached the market in 2022. Development continues today, such as expanding indications and exploring combination therapies. Although it is sometimes said that “10 years is short in drug development,” I don’t feel the path was smooth, as we faced unexpected research data and experienced numerous rejections during paper submissions. This is not limited to biology or medicine, it’s probably the same in any field of research.
Nevertheless, I am reminded that I was able to enjoy the journey and come this far because of my laboratory colleagues, collaborators, everyone involved in industry-academia-government partnerships, and the many people who supported my research. My research is still a work in progress, with many challenges remaining. With this award as encouragement, I would like to continue my research, deepen my understanding of biological phenomena and translate that knowledge into medical practice.

